# CONMED Corp (CNMD)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/conmed-corp/ JSON: https://steadybase.io/company/conmed-corp.json Checked Nov 10, 2026. Latest filing read: Oct 28, 2026.

## Company

- Legal name: CONMED Corp
- Ticker: CNMD (NYSE)
- SEC CIK: 0000816956
- Industry: Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Headquarters: Largo, FL
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: conmed.com
- LinkedIn: https://www.linkedin.com/company/conmed-corporation
- Next earnings date: Jan 27, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $1.4B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 17, 2026). Source: https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/0000816956-26-000009-index.html
- Operating income: $102.6M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 17, 2026). Source: https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/0000816956-26-000009-index.html
- Net income: $47.1M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 17, 2026). Source: https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/0000816956-26-000009-index.html
- SG&A: $592.0M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 17, 2026). Source: https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/0000816956-26-000009-index.html
- Employees: 3,900 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/cnmd-20251231.htm
- Shares outstanding: 29,803,323 as of Oct 26, 2026 (10-Q filed Oct 28, 2026). Source: https://www.sec.gov/Archives/edgar/data/816956/000081695626000111/0000816956-26-000111-index.html
- Auditor: Pricewaterhousecoopers LLP, Victor, New York, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/cnmd-20251231.htm

## Business

general economic and business conditions, including, without limitation, a potential economic downturn, supply chain challenges and constraints, including the availability and cost of materials, the effects of inflation, and increased interest rates;

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/cnmd-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $1.4B | $102.6M | $47.1M | $592.0M |
| Dec 31, 2024 | $1.3B | $200.3M | $132.4M | $478.3M |
| Dec 31, 2023 | $1.2B | $120.6M | $64.5M | $503.0M |
| Dec 31, 2022 | $1.0B | $70.1M | -$80.6M | $454.0M |
| Dec 31, 2021 | $1.0B | $109.7M | $62.5M | $414.8M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/conmed-corp.json

## Officers and directors

- Patrick J. Beyer, CONMED’s President and Chief Executive Officer. LinkedIn: https://linkedin.com/in/pat-beyer-8131a818. Source: 8-K filed Oct 28, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000110/cnmdearningsrelease9302026.htm
- Patrick Beyer, President and Chief Executive Officer. Source: 8-K filed Jun 17, 2026, https://www.sec.gov/Archives/edgar/data/816956/000207709626000203/ea0295016-8k_conmed.htm
- Pat Beyer, President & CEO. LinkedIn: https://linkedin.com/in/pat-beyer-8131a818. Source: Form 4 filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000041/0000816956-26-000041-index.htm
- John E. Gallagher, Executive Vice President & CFO. LinkedIn: https://linkedin.com/in/john-gallagher-1840681. Source: Form 4 filed Jul 17, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000096/0000816956-26-000096-index.htm
- Todd W. Garner, Executive Vice President & CFO. LinkedIn: https://linkedin.com/in/todd-garner-930408. Source: Form 4 filed Nov 7, 2025, https://www.sec.gov/Archives/edgar/data/816956/000081695625000059/0000816956-25-000059-index.htm
- Kimberly Lockwood, Interim Corporate Controller. Source: 8-K filed Jun 17, 2026, https://www.sec.gov/Archives/edgar/data/816956/000207709626000203/ea0295016-8k_conmed.htm
- Hollie K. Foust, General Counsel & Corp Sec. Source: 4/A filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000035/0000816956-26-000035-index.htm
- John D. Ferrell, Executive Vice President - HR. Source: 4/A filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000033/0000816956-26-000033-index.htm
- Peter K. Shagory, EVP, STRAT & CORP DEVT. Source: 4/A filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000031/0000816956-26-000031-index.htm
- Andrew James Moller, VP Corporate Controller. Source: Form 4 filed Mar 4, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000015/0000816956-26-000015-index.htm
- Johonna Marie Pelletier, Treasurer and VP, Tax. Source: Form 4 filed Mar 4, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000023/0000816956-26-000023-index.htm
- Andrew Moller, Principal Accounting Officer. Source: 10-K filed Feb 17, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/cnmd-20251231.htm
- Richard Glaze, Chief Information Officer. Source: Form 4 filed Nov 24, 2025, https://www.sec.gov/Archives/edgar/data/816956/000081695625000063/0000816956-25-000063-index.htm
- Laverne Council, Chair of the Board. Source: 10-K filed Feb 17, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/cnmd-20251231.htm
- Celine Martin, director. Source: 8-K filed May 20, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000057/cnmd-20260518.htm
- Jeff Mirviss, director. Source: 8-K filed May 20, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000057/cnmd-20260518.htm
- Brent Lalomia, Executive VP RA, QA. LinkedIn: https://linkedin.com/in/brent-lalomia-b2512355. Source: 4/A filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000039/0000816956-26-000039-index.htm
- Matthew Schabacker, VP GM Advanced Surgical. Source: 4/A filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000037/0000816956-26-000037-index.htm
- Brian P. Concannon, Director. Source: 10-K filed Feb 17, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/cnmd-20251231.htm
- Charles M. Farkas, Director. Source: 10-K filed Feb 17, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/cnmd-20251231.htm
- David Bronson, Director. Source: 10-K filed Feb 17, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/cnmd-20251231.htm
- Kim Kelderman, Director. Source: 10-K filed Feb 17, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/cnmd-20251231.htm
- Mark Kaye, Director. Source: 10-K filed Feb 17, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/cnmd-20251231.htm
- Barbara J. Schwarzentraub, Board member (per proxy). Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000047/cnmd-20260407.htm
- Hollie Foust, EVP, General Counsel and Corporate Secretary. LinkedIn: https://linkedin.com/in/hollie-foust-20856389. Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/816956/000081695626000047/cnmd-20260407.htm

## Recent 8-K events

- Oct 28, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/816956/000081695626000110/cnmd-20261028.htm
- Jul 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/816956/000081695626000101/cnmd-20260729.htm
- Jun 17, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/816956/000207709626000203/ea0295016-8k_conmed.htm
- Jun 4, 2026: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/816956/000117494726000639/form8k-36002_cnmd.htm
- Jun 1, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/816956/000207709626000190/ea0292464-8k_conmed.htm
- May 20, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/816956/000081695626000057/cnmd-20260518.htm
- Apr 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/816956/000081695626000051/cnmd-20260429.htm
- Mar 13, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/816956/000121390026027658/ea0280482-8k_conmed.htm
- Jan 28, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/816956/000081695626000006/cnmd-20260128.htm
- Jan 12, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/816956/000117494726000024/form8k-35073_cnmd.htm

## Insider trades (Form 4)

- Nov 21, 2025: Richard Glaze (Chief Information Officer) sold 257 shares, about $10,591. Source: https://www.sec.gov/Archives/edgar/data/816956/000081695625000063/0000816956-25-000063-index.htm
- Nov 6, 2025: Todd W. Garner (Executive Vice President & CFO) sold 3,500 shares, about $150,500. Source: https://www.sec.gov/Archives/edgar/data/816956/000081695625000059/0000816956-25-000059-index.htm
- Sep 12, 2025: Charles Farkas (Director) sold 2,000 shares, about $107,053. Source: https://www.sec.gov/Archives/edgar/data/816956/000081695625000042/0000816956-25-000042-index.htm
- Aug 7, 2025: Todd W. Garner (Executive Vice President & CFO) sold 598 shares, about $31,365. Source: https://www.sec.gov/Archives/edgar/data/816956/000081695625000033/0000816956-25-000033-index.htm

## What management said

- "Our third quarter organic, constant currency net sales growth was consistent with our expectations and our adjusted diluted EPS exceeded them, reflecting our team’s strong execution" Patrick J. Beyer, CONMED’s President and Chief Executive Officer (8-K filed Oct 28, 2026). Source: https://www.sec.gov/Archives/edgar/data/816956/000081695626000110/cnmdearningsrelease9302026.htm

## Latest filings

- 8-K filed Oct 28, 2026: https://www.sec.gov/Archives/edgar/data/816956/000081695626000110/cnmd-20261028.htm
- 10-K filed Feb 17, 2026: https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/cnmd-20251231.htm
- 10-Q filed Oct 28, 2026: https://www.sec.gov/Archives/edgar/data/816956/000081695626000111/cnmd-20260930.htm
- DEF 14A filed Apr 7, 2026: https://www.sec.gov/Archives/edgar/data/816956/000081695626000047/cnmd-20260407.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/